Open AccessBETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors
Author(s) -
Santosh Kesari,
Alberto Bessudo,
Brian Gastman,
Anthony P. Conley,
Victoria M. Villaflor,
Lisle M. Nabell,
DeLisa Madere,
Emma Chacon,
Christina Spencer,
Li Li,
Christopher Larson,
Tony Reid,
Scott Caroen,
Bryan Oronsky,
Meaghan Stirn,
Jeannie Williams,
Minal Barve
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0481
Subject(s) - medicine , oncolytic virus , immune checkpoint , refractory (planetary science) , cd8 , immunotherapy , clinical trial , cancer research , blockade , cancer immunotherapy , immune system , combination therapy , oncology , immunology , receptor , biology , astrobiology